John Goldberg
Technik-/Wissenschafts-/F&E-Leiter bei RAFAEL HOLDINGS, INC.
Vermögen: 344 $ am 31.12.2023
Aktive Positionen von John Goldberg
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| RAFAEL HOLDINGS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 20.11.2023 | - |
Karriereverlauf von John Goldberg
Ehemalige bekannte Positionen von John Goldberg
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| ONCORUS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 22.02.2022 | 30.06.2023 |
| Corporate Officer/Principal | 01.10.2018 | 22.02.2022 | |
| AGENUS INC. | Technik-/Wissenschafts-/F&E-Leiter | - | - |
H3 Biomedicine, Inc.
 H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Corporate Officer/Principal | - | - |
Ausbildung von John Goldberg
| UMass Chan Medical School | Doctorate Degree |
| The University of Chicago | Undergraduate Degree |
Statistik
International
| Vereinigte Staaten | 7 |
Operativ
| Chief Tech/Sci/R&D Officer | 3 |
| Corporate Officer/Principal | 2 |
| Doctorate Degree | 1 |
Sektoral
| Health Technology | 4 |
| Consumer Services | 3 |
| Finance | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| ONCORUS, INC. | Health Technology |
| AGENUS INC. | Health Technology |
| RAFAEL HOLDINGS, INC. | Finance |
| Private Unternehmen | 1 |
|---|---|
H3 Biomedicine, Inc.
H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Health Technology |
- Börse
- Insiders
- John Goldberg
- Erfahrung
